|Articles|February 11, 2016
Biotech Selects Almac's Interactive Response Platform
A global biotech will be migrating to its newest generation Interactive Response Technology (IRT), platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Advertisement
Almac Clinical Technologies, part of the Almac Group, has announced that a global biotechnology company will be migrating to its newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Read the
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Quantifying the Net Financial Value of Deploying Risk-Based Quality Management
2
PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety
3
ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics
4
ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support
5